Literature DB >> 2186178

Chemical synthesis of biologically active tat trans-activating protein of human immunodeficiency virus type 1.

R Chun1, C G Glabe, H Fan.   

Abstract

Full-length (86-residue) polypeptide corresponding to the human immunodeficiency virus type 1 tat trans-activating protein was chemically synthesized on a semiautomated apparatus, using an Fmoc amino acid continuous-flow strategy. The bulk material was relatively homogeneous, as judged by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and isoelectric focusing, and it showed trans-activating activity when scrape loaded into cells containing a human immunodeficiency virus long terminal repeat-chloramphenicol acetyl-transferase reporter plasmid. Reverse-phase high-pressure liquid chromatography yielded a rather broad elution profile, and assays across the column for biological activity indicated a sharper peak. Thus, high-pressure liquid chromatography provided for enrichment of biological activity. Fast atom bombardment-mass spectrometry of tryptic digests of synthetic tat identified several of the predicted tryptic peptides, consistent with accurate chemical synthesis.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2186178      PMCID: PMC249495     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  23 in total

1.  A new micro-test for the detection of incomplete coupling reactions in solid-phase peptide synthesis using 2,4,6-trinitrobenzenesulphonic acid.

Authors:  W S Hancock; J E Battersby
Journal:  Anal Biochem       Date:  1976-03       Impact factor: 3.365

2.  Bioassay for trans-activation using purified human immunodeficiency virus tat-encoded protein: trans-activation requires mRNA synthesis.

Authors:  R Gentz; C H Chen; C A Rosen
Journal:  Proc Natl Acad Sci U S A       Date:  1989-02       Impact factor: 11.205

3.  Autonomous functional domains of chemically synthesized human immunodeficiency virus tat trans-activator protein.

Authors:  M Green; P M Loewenstein
Journal:  Cell       Date:  1988-12-23       Impact factor: 41.582

4.  The location of cis-acting regulatory sequences in the human T cell lymphotropic virus type III (HTLV-III/LAV) long terminal repeat.

Authors:  C A Rosen; J G Sodroski; W A Haseltine
Journal:  Cell       Date:  1985-07       Impact factor: 41.582

5.  Location of the trans-activating region on the genome of human T-cell lymphotropic virus type III.

Authors:  J Sodroski; R Patarca; C Rosen; F Wong-Staal; W Haseltine
Journal:  Science       Date:  1985-07-05       Impact factor: 47.728

6.  Mutational analysis of HIV-1 Tat minimal domain peptides: identification of trans-dominant mutants that suppress HIV-LTR-driven gene expression.

Authors:  M Green; M Ishino; P M Loewenstein
Journal:  Cell       Date:  1989-07-14       Impact factor: 41.582

7.  HIV/HTLV gene nomenclature.

Authors:  R Gallo; F Wong-Staal; L Montagnier; W A Haseltine; M Yoshida
Journal:  Nature       Date:  1988-06-09       Impact factor: 49.962

8.  Human immunodeficiency virus 1 tat protein binds trans-activation-responsive region (TAR) RNA in vitro.

Authors:  C Dingwall; I Ernberg; M J Gait; S M Green; S Heaphy; J Karn; A D Lowe; M Singh; M A Skinner; R Valerio
Journal:  Proc Natl Acad Sci U S A       Date:  1989-09       Impact factor: 11.205

9.  Cellular uptake of the tat protein from human immunodeficiency virus.

Authors:  A D Frankel; C O Pabo
Journal:  Cell       Date:  1988-12-23       Impact factor: 41.582

10.  Trans-activator gene of human T-lymphotropic virus type III (HTLV-III).

Authors:  S K Arya; C Guo; S F Josephs; F Wong-Staal
Journal:  Science       Date:  1985-07-05       Impact factor: 47.728

View more
  3 in total

1.  Osteocalcin binds tightly to the gamma-glutamylcarboxylase at a site distinct from that of the other known vitamin K-dependent proteins.

Authors:  R J Houben; D Jin; D W Stafford; P Proost; R H Ebberink; C Vermeer; B A Soute
Journal:  Biochem J       Date:  1999-07-15       Impact factor: 3.857

2.  Effects of the Tat basic domain on human immunodeficiency virus type 1 transactivation, using chemically synthesized Tat protein and Tat peptides.

Authors:  E Vives; P Charneau; J van Rietschoten; H Rochat; E Bahraoui
Journal:  J Virol       Date:  1994-05       Impact factor: 5.103

3.  In vitro and in vivo binding of human immunodeficiency virus type 1 Tat protein and Sp1 transcription factor.

Authors:  K T Jeang; R Chun; N H Lin; A Gatignol; C G Glabe; H Fan
Journal:  J Virol       Date:  1993-10       Impact factor: 5.103

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.